Results 21 to 30 of about 7,917 (182)
Vigabatrin for Infantile Spasms
The efficacy of vigabatrin (VGB) as the first, and adrenocorticotropin hormone (ACTH) or valproate (VPA) as the second, treatment of choice for newly diagnosed infantile spasms was evaluated in 42 infants treated at the University of Helsinki, Finland.
J Gordon Millichap
doaj +2 more sources
Long-term developmental outcome in infantile epileptic spasms syndrome after high-dose prednisolone and vigabatrin treatment. [PDF]
Abstract Objective To evaluate long‐term developmental outcomes and identify independent predictors of favorable developmental outcomes at 3 years of age in children with infantile epileptic spasms syndrome (IESS) treated with a standardized stepwise vigabatrin and high‐dose prednisolone protocol.
Jang S +5 more
europepmc +2 more sources
Ocular examinations, findings, and toxicity in children taking vigabatrin. [PDF]
BACKGROUND: The antiepileptic medication vigabatrin has been associated with ocular toxicity, and close ophthalmic monitoring has been recommended; however, there is no clear consensus regarding the value and feasibility of such monitoring in children ...
Han, Ying +6 more
core +3 more sources
Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality.
James W, Wheless +2 more
openaire +3 more sources
Study of visual field defects in patients with epilepsy receiving Vigabatrin [PDF]
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely prescribed in Europe and Asia between 1989 and 1997 for drug resistant, partial epilepsy and has been associated with visual field defects.
Gonzalez, Pedro Antonio
core +6 more sources
The new antiepileptic drugs introduced over the last decade provide a welcome increase in the therapeutic options available for the 25% of children with epilepsy who remain refractory to traditional therapy.1 In the mid 1980s, vigabatrin (VGB) was the first of these to be made available in clinical practice.
H, Lewis, S J, Wallace
openaire +2 more sources
Possible analgesic effect of vigabatrin in animal experimental chronic neuropathic pain [PDF]
Since anticonvulsants have been used for treating neuralgias, an interest has arisen to experimentally test vigabatrin for its gabaergic mechanism of action.
NILZA D. ALVES +4 more
doaj +1 more source
Vigabatrin induced Cell loss in the Cerebellar Cortex of Albino Rats [PDF]
Background: Vigabatrin is used as the drug of choice in resistant epilepsy and infantile spasms. Ataxia, tremors and abnormal gait have been frequently reported following the use of this drug, indicating an involvement of the cerebellum.
Deepa Singh +2 more
doaj +1 more source
ABSTRACT:Vigabatrin (VGB) is a recently-released antiepileptic drug which works by a clearlydefined mechanism of action: inhibition of GABA transaminase leading to an elevation of brain GABA concentration. It has been proven effective, mainly as an add-on agent, in complex partial and secondarily generalized seizures in both adults and children as well
openaire +2 more sources
Background Infantile spasms represent a serious epileptic syndrome that occurs in the early infantile age. ACTH and Vigabatrin are actively investigated drugs in its treatment.
Ishaque Sidra +3 more
doaj +1 more source

